Literature DB >> 28485019

Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.

M Tasani1, P Ancliff2, M Glover1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28485019     DOI: 10.1111/bjd.15640

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  7 in total

1.  [Vascular anomalies. Part I: vascular tumors].

Authors:  S Mylonas; S Brunkwall; J Brunkwall
Journal:  Chirurg       Date:  2018-03       Impact factor: 0.955

Review 2.  [Acute complications of vascular anomalies in childhood].

Authors:  M Fließer; A Teichler; P H Höger
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

3.  Use of Sirolimus in a Premature Neonate With Kaposiform Hemangioedema.

Authors:  Jason Koury; Miel Brown; Suzzette Sturtevant; Cody Wiley; Linda Felton
Journal:  J Pediatr Pharmacol Ther       Date:  2021-02-15

4.  Kaposiform hemangioendothelioma without cutaneous involvement.

Authors:  Yi Ji; Siyuan Chen; Lizhi Li; Kaiying Yang; Chunchao Xia; Li Li; Gang Yang; Feiteng Kong; Guoyan Lu; Xingtao Liu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-06       Impact factor: 4.553

Review 5.  Kaposiform hemangioendothelioma: current knowledge and future perspectives.

Authors:  Yi Ji; Siyuan Chen; Kaiying Yang; Chunchao Xia; Li Li
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

Review 6.  Vascular Anomalies of the Head and Neck: A Pediatric Overview.

Authors:  Juan Putra; Alyaa Al-Ibraheemi
Journal:  Head Neck Pathol       Date:  2021-03-15

7.  Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: a Case Report and Review of the Literature.

Authors:  Matteo Chinello; Daniela Di Carlo; Francesca Olivieri; Rita Balter; Massimiliano De Bortoli; Virginia Vitale; Ada Zaccaron; Elisa Bonetti; Alice Parisi; Simone Cesaro
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-07-01       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.